This inventor holds 1 USPTO granted patent, plus 1 CIPO patent and 1 EPO patent. Top assignee: University College Cardiff Consultants Limited. Active years: 2025.
Company Filing History:
Years Active: 2025
Title: Hanni Uusi-Kerttula: Innovator in Oncolytic Adenovirus Research
Introduction
Hanni Uusi-Kerttula is a prominent inventor based in Helsinki, Finland. She has made significant contributions to the field of cancer treatment through her innovative research on modified adenoviruses. Her work focuses on developing pharmaceutical compositions that utilize these modified viruses to combat cancer effectively.
Latest Patents
Hanni Uusi-Kerttula holds 1 patent for her invention concerning modified oncolytic adenoviruses of serotype Ad5. This invention includes a pharmaceutical composition that comprises a modified adenovirus designed to treat cancer. The modified adenovirus features several key mutations, including point mutations in the hexon hypervariable region to prevent binding with coagulation factor 10, mutations in the fiber knob region to inhibit binding with the coxsackie and adenovirus receptor, and mutations in the penton integrin binding motif to prevent binding with integrins.
Career Highlights
Hanni Uusi-Kerttula has established herself as a leading figure in her field. She is affiliated with University College Cardiff Consultants Limited, where she continues her research and development efforts. Her innovative approach to cancer treatment has garnered attention and respect within the scientific community.
Collaborations
Hanni collaborates with various professionals in her field, including her coworker Alan Parker. Their combined expertise contributes to advancing research in oncolytic adenoviruses and cancer therapies.
Conclusion
Hanni Uusi-Kerttula's work in the development of modified adenoviruses represents a significant advancement in cancer treatment. Her innovative research and dedication to her field continue to inspire and pave the way for future breakthroughs.